Lymphoproliferative neoplasms and renal cell carcinoma of clear cell type – Where is the link?

Zorica Cvetković; Nada Suvajdžić-Vuković; Bora Cvetković

doi:10.2298/5760

Zorica Cvetković Department of Hematology, Clinical Hospital Center Zemun, Belgrade, Serbia
Nada Suvajdžić-Vuković Clinic of Hematology Clinical Center of Serbia Faculty of Medicine University of Belgrade, Belgrade
Bora Cvetković Department of Urology, Clinical Hospital Center Zemun, Belgrade

DOI: https://doi.org/10.2298/5760

Keywords: lymphoproliferative disorders, neoplasms, kidney noplasms, comorbidity, risk factors, prognosis,

Abstract

Introduction. The etiology of higher than expected occurrence of lymphoproliferative neoplasms (LPN) and renal cell carcinoma (RCC) in the same patient has not yet been clarified. Several explanations for this co-occurrence have been postulated: prior cytotoxic treatment, viral infections, immunomodulatory effects of tumor itself and shared genetic and/or environmental factors. Case report. Medical records of 680 consecutive patients with LPN and 570 consecutive patients with RCC diagnosed between January 1997 and December 2011 in two centers were retrospectively analyzed. Co-occurrence of both diseases was registered in five of the patients (3 males, 2 females) and their demographic, clinical and pathological characteristics were presented. Conclusion. Synchronous occurrence of LPN neoplasms and RCC or a short latent period between the diagnoses of these two malignancies in the same patient, as well as the lack of cytotoxic treatment for firstly occurring neoplasm implies a possible common pathobiology of both diseases.

References

Vardiman JW, Brunning RD, Arber DA, le Beau MM. Introduction and overview of the classification of the myeloid neoplasms. In: Swerdlow SH, Campo E, Harris LN, Jaffe ES, Pileri SA, Stein H, editors. WHO classification of tumours of hematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 127−9.

Nishikubo CY, Kunkel LA, Figlin R, Belldegrun A, Rosen P, Elashoff R, et al. An association between renal cell carcinoma and lymphoid malignancies. A case series of eight patients. Cancer 1996; 78(11): 2421−6.

Liu H, Hemminki K, Sundquist J. Renal cell carcinoma as first and second primary cancer: etiological clues from the Swedish Family-Cancer Database. J Urol 2011; 185(6): 2045−9.

Ojha RP, Evans EL, Felini MJ, Singh KP, Thertulien R. The asso-ciation between renal cell carcinoma and multiple myeloma: insights from population-based data. BJU Int 2011; 108(6): 825−30.

Anderson CM, Pusztai L, Palmer JL, Cabanillas F, Ellerhorst JA. Coincident renal cell carcinoma and nonHodgkin's lymphoma: the M. D. Anderson experience and review of the literature. J Urol 1998; 159(3): 714−7.

Ohsawa M, Hashimoto M, Yasunaga Y, Shingu N, Aozasa K. Char-acteristics of non-Hodgkin's lymphoma complicated by renal cell malignancies. Oncology 1998; 55(5): 482−6.

Kunthur A, Wiernik PH, Dutcher JP. Renal parenchymal tumors and lymphoma in the same patient: case series and review of the literature. Am J Hematol 2006; 81(4): 271−80.

Badros A, Karakunnel J, Dawson N. Multiple myeloma and renal cell carcinoma possible association. Leuk Lymphoma 2007; 48(8): 1662−4.

Bhandari MS, Mazumder A, Jagannath S, Vesole DH. Association between renal cell carcinoma and plasma cell dyscrasias: a case series of six patients. Clin Lymphoma Myeloma 2008; 8(3): 188−90.

Ozturk MA, Dane F, Kaygusuz I, Asmaz O, Uzay A, Bayik M, et al. Synchronous renal cell carcinoma and multiple myeloma: report of two cases and review of the literature. J BUON 2009; 14(3): 511−4.

Serefhanoglu S, Buyukasik Y, Goker H, Akin SC, Akin S, Sayinalp N, et al. Concomitant renal cell carcinoma and lymphoid ma-lignancies: a case series of five patients and review of the litera-ture. Med Oncol 2010; 27(1): 55−8.

National Cancer Institute. Surveillance, Epidemiology and End results data. 2014. Available from: http://seer.cancer.gov/data/index:htm.

Travis LB, Curtis RE, Boice JD, Hankey BF, Fraumeni JF. Second cancers following non-Hodgkin's lymphoma. Cancer 1991; 67(7): 2002−9.

Travis LB, Curtis RE, Glimelius B, Holowaty E, Van Leeuwen FE, Lynch CF, et al. Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst 1993; 85(23): 1932–7.

Beisland C, Talleraas O, Bakke A, Norstein J. Multiple primary malignancies in patients with renal cell carcinoma: a national population-based cohort study. BJU Int 2006; 97(4): 698−702.

Chakraborty S, Tarantolo SR, Batra SK, Hauke RJ. Incidence and prognostic significance of second primary cancers in renal cell carcinoma. Am J Clin Oncol 2013; 36(2): 132−42.

Lossos C, Ferrell A, Duncan R, Lossos IS. Association between non-Hodgkin lymphoma and renal cell carcinoma. Leuk Lymphoma 2011; 52(12): 2254−61.

Choueiri TK, Baz RC, McFadden CM, Khasawneh M, Karam MA, Kelly M, et al. An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications. BJU Int 2008; 101(6): 712−5.

Rabbani F, Grimaldi G, Russo P. Multiple primary malignancies in renal cell carcinoma. J Urol 1998; 160(4): 1255−9.

Rabbani F, Reuter VE, Katz J, Russo P. Second primary malignancies associated with renal cell carcinoma: influence of histologic type. Urology 2000; 56(3): 399−403.

Cairns P. Renal cell carcinoma. Cancer Biomark 2010; 9(1−6): 461−73.

Contreras-Ibáñez JA, Díaz-Gómez L, Muriel-Cueto P. Renal synchronous carcinoma of clear cells with non-hodgkin lymphoma of phenotype b of type MALT. Actas Urol Esp 2010; 34(9): 818−9.

David AW, Indrani S, Apurva S, Sukria N, Benjamin P. Burkitt's lymphoma of the ileum with renal cell carcinoma. Can J Surg 2008; 51(4): E77−8.

Chang MY, Chen YM, Chen YC, Tian YC, Fang JT, Yang CW. Concurrent renal cell carcinoma and central nervous system lymphoma in a patient with autosomal dominant polycystic kidney disease. Med Princ Pract 2009; 18(6): 486−9.

Terpos E, Eleutherakis-Papaiakovou V, Dimopoulos M. Clinical implications of chromosomal abnormalities in multiple myeloma. Leuk Lymphoma 2006; 47(5): 803−14.

Allory Y, Culine S, de la Taille A. Kidney cancer pathology in the new context of targeted therapy. Pathobiology 2011; 78(2): 90−8.

Burger R. Impact of interleukin-6 in hematological malignancies. Transfus Med Hemother 2013; 40(5): 336−43.

Anderson KC. Multiple Myeloma. Advances in disease biology: therapeutic implications. Semin Hematol 2001; 38(2 Suppl 3): 6−10.

Song G, Li Y, Jiang G. Role of VEGF/VEGFR in the patho-genesis of leukemias and as treatment targets (Review). Oncol Rep 2012; 28(6): 1935−44.

Polimeno M, Napolitano M, Costantini S, Portella L, Esposito A, Ca-pone F, et al. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, ep-idermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma. BJU Int 2013; 112(5): 686−96.

Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, et al. Tar-geting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther 2014; 141(2): 125−39.

Vano YA, Tartour E, Fournier LS, Beuselinck B, Mejean A, Oudard S. Prognostic factors in patients with advanced renal cell carci-noma treated with VEGF-targeted agents. Expert Rev Anti-cancer Ther 2014; 14(5): 523−42.

Podar K, Anderson KC. Emerging therapies targeting tumor vas-culature in multiple myeloma and other hematologic and solid malignancies. Curr Cancer Drug Targets 2011; 11(9): 1005−24.

Morgan GJ, Davies FE, Linet M. Myeloma aetiology and epide-miology. Biomed Pharmacother 2002; 56(5): 223−34.

Lipworth L, Tarone RE, Lund L, McLaughlin JK. Epidemiologic characteristics and risk factors for renal cell cancer. Clin Epi-demiol 2009; 1: 33−43.